Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe current standard of care in the first line is a combination of Genentech’s Herceptin...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 2 hours agoThe technology is behind some of the biggest medicines on the market, including Johnson & Johnson's...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 4 days agoARX788 (anvatabart opadotin), a HER2-targeting antibody conjugated to Amberstatin 269 with a...
Top Analyst Reports for Roche, Wells Fargo & GE Aerospace
Zacks via Yahoo Finance· 3 days agoToday's Research Daily features new research reports on 16 major stocks, including Roche Holding AG...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 3 days agoDr. Dennis Slamon, a world-renowned oncologist and scientist whose groundbreaking research has...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 3 days agoIn 2024, Teva expects Uzedy sales of approximately $80 million. Teva markets biosimilar versions of...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 5 days ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision
FierceBiotech· 6 days agoAs zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing
